Janne M. Toivonen 1 , 2 , 3 , 4 , * , David Sanz-Rubio 1 , 2 , Óscar López-Pérez 1 , 2 , 3 , 4 , 5 , 6 , Alba Marín-Moreno 7 , Rosa Bolea 2 , 3 , 5 , Rosario Osta 1 , 2 , 3 , 4 , Juan J. Badiola 2 , 3 , 5 , Pilar Zaragoza 1 , 2 , 3 , 4 , Juan-Carlos Espinosa 7 , Juan-Maria Torres 7 , Inmaculada Martín-Burriel 1 , 2 , 3 , 4 , 5
15 June 2020
MicroRNAs (miRNAs) may contribute to the development and pathology of many neurodegenerative diseases, including prion diseases. They are also promising biomarker candidates due to their stability in body fluids. We investigated miRNA alterations in a Tg501 mouse model of prion diseases that expresses a transgene encoding the goat prion protein ( PRNP). Tg501 mice intracranially inoculated with mouse-adapted goat scrapie were compared with age-matched, mock inoculated controls in preclinical and clinical stages. Small RNA sequencing from the cervical spinal cord indicated that miR-223-3p, miR-151-3p, and miR-144-5p were dysregulated in scrapie-inoculated animals before the onset of symptoms. In clinical-stage animals, 23 significant miRNA alterations were found. These miRNAs were predicted to modify the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways including prion disease, extracellular matrix interactions, glutaminergic synapse, axon guidance, and transforming growth factor-beta signaling. MicroRNAs miR-146a-5p (up in cervical spinal cord) and miR-342-3p (down in cervical spinal cord, cerebellum and plasma), both indicated in neurodegenerative diseases earlier, were verified by quantitative real-time polymerase chain reaction (qRT-PCR). Minimal changes observed before the disease onset suggests that most miRNA alterations observed here are driven by advanced prion-associated pathology, possibly limiting their use as diagnostic markers. However, the results encourage further mechanistic studies on miRNA-regulated pathways involved in these neurodegenerative conditions.